We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Open Science Drug Discovery Approach Targets Neurodegenerative Disease
News

Open Science Drug Discovery Approach Targets Neurodegenerative Disease

Open Science Drug Discovery Approach Targets Neurodegenerative Disease
News

Open Science Drug Discovery Approach Targets Neurodegenerative Disease

With the help of a $1.5-million grant, University of Toronto's Aled Edwards (right) and business partner Owen Roberts (left) will forgo patents and profits to tackle diseases like Parkinson's and ALS. Credit: Chris Sorensen
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Open Science Drug Discovery Approach Targets Neurodegenerative Disease"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Parkinson’s disease and Amyotrophic Lateral Sclerosis, or ALS, are the newest frontiers for open science drug discovery, a global movement led by University of Toronto researchers that puts knowledge sharing and medication affordability ahead of patents and profits.


Thanks to $1.5 million from Toronto’s Krembil Foundation, Medicines 4 Neurodegenerative Diseases, also known as M4ND Pharma, will pursue promising new genetic drug targets for these intractable nervous system disorders.


It will be the world’s second drug discovery company committed to open science after Medicines 4 Kids, or M4K Pharma, which was launched by U of T's Aled Edwards and business partner Owen Roberts in 2017 to develop a novel drug for an uncommon but fatal childhood brain cancer.


“When we started M4K, many people thought an open approach to late-stage drug development might only be applicable to rare or neglected diseases, if at all,” says Edwards, a professor of molecular genetics in U of T's Faculty of Medicine. “But we’re getting unexpected funding and scientific contributions from industry, academic and clinical sources, and slowly but surely we’re advancing a medicine through the pipeline.


“It’s time to move the goal posts again on what’s possible with open science.”


Open science is a way for researchers to speed up scientific discovery by sharing data and knowledge quickly and publicly, unencumbered by patents and the peer review publishing process. The movement gathered force in the life sciences in the 1990s with the Human Genome Project, and spread to protein structures and then early-stage drug discovery through the Structural Genomics Consortium (SGC), which Edwards co-founded and now leads as director.


The non-profit SGC has generated considerable private and public investment and several spin-out companies, but there remains a gap in late-stage drug development.


Like M4K, M4ND will not seek patents on its findings. It will instead rely on regulatory protections available in several countries, including data exclusivity for drug sponsors to prevent generic competition, and orphan drug exclusivity for rare diseases. These and other existing protections, says Edwards, are likely sufficient to attract commercial partners willing to manufacture, distribute and sell medications at reasonable prices.


As well, M4ND will also be owned by the Agora Open Science Trust, a Canadian charity that supports open science for the public good.  M4ND will donate any proceeds generated through commercial partnerships back to the charity.


The researchers will share their progress with the scientific community through regular online meetings that are open to all and posted on YouTube. They will also make data widely available – for example through the SGC’s open lab notebooks initiative.


“Every player in the system appreciates the idea of affordable medicines faster, but it’s been incredibly challenging to make it happen because the system is complicated,” says Edwards.


“The key was to invent a different business model, and we’re extraordinarily happy that industry, academia and others have been delighted to contribute.”

This article has been republished from materials provided by the University of Toronto. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement